美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Franklin Genomic Advancements ETF

43.16

+1.293.07%

成交量：289

成交額：1.25萬

市值：3,237.00萬

市盈率：- -

高：43.16

開：43.16

低：43.16

收：41.87

52周最高：43.51

52周最低：29.80

股本：75.00萬

流通股本：75.00萬

量比：2.04

換手率：0.04%

股息：0.14

股息率：0.33%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

代謝紊亂生物技術公司Vogenx(VOGX.US)IPO定價11-13美元/股擬募資7500萬美元

代謝紊亂生物技術公司Vogenx(VOGX.US)IPO定價11-13美元/股擬募資7500萬美元

美國食品藥品監督管理局（FDA）批准了Freenome公司用於結直腸癌篩查的血液檢測

美股異動 | CRISPR基因編輯公司Scribe Therapeutics(SCTX.US)登陸美股市場開盤後升逾59%

Krystal Biotech決定終止臨床研究，以推動KB801進入關鍵性試驗；SEC文件稱未觀察到安全性問題

Krystal Biotech 披露：已終止研究無更多受試者數據更新，關鍵性試驗結果將適時公布

建築公司Tutor Perini入選標普小盤股股價大漲

據彭博，總部位於美國的生物技術公司Axiom尋求在香港上市。

標普道瓊斯指數宣佈：Krystal Biotech Inc.將取代Taylor Morrison Home Corporation進入標普400中型股指數

普洛藥業：擬1000萬元投資設立生物技術公司構成關聯交易

億帆醫藥首個HMOs系列合成生物技術產品2'-FL取得食品生產許可證

特寶生物：生物技術創新融合及產業化基地項目主體結構封頂

港股異動丨生物技術板塊迎大反彈，銀諾醫藥隨行業暖風大升逾7%

Natera因癌症檢測獲得歐盟認證而股價上漲

中國農科院生物所與華大智造共建「數字細胞時空組學實驗室」

生物技術公司Scribe Therapeutics(SCTX.US)申請美股IPO 擬籌資至多7500萬美元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/HELX/news?page=3"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"HELX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","market":"US","secType":"STK","nameCN":"Franklin Genomic Advancements ETF","latestPrice":43.16,"timestamp":1789660139487,"preClose":41.8729,"halted":0,"volume":289,"delay":0,"changeRate":0.030738257918605953,"floatShares":750000,"shares":750000,"eps":0,"marketStatus":"交易中","change":1.2871,"latestTime":"09-17 11:49:46 EDT","open":43.16,"high":43.16,"low":43.16,"amount":12467.14499,"amplitude":0,"askPrice":43.24,"askSize":620,"bidPrice":43.08,"bidSize":600,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789675200000},"marketStatusCode":2,"adr":0,"exchange":"CBOE","adjPreClose":41.8729,"sharesOutstanding":650000,"nav":41.868,"aum":31401033.77,"dividendRate":0.003299,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":41.8273,"preClose":41.8729,"latestTime":"16:10 EDT","volume":6,"amount":251.1462,"timestamp":1789589404188,"change":-0.0456,"changeRate":-0.001089,"amplitude":0},"volumeRatio":2.036094,"impliedVol":0.0896,"impliedVolPercentile":0.3426},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","floatShares":750000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.036094,"shares":750000,"dividePrice":0.1424,"high":43.16,"amplitude":0,"preClose":41.8729,"low":43.16,"week52Low":29.8,"pbRate":"--","week52High":43.5089,"institutionHeld":0,"latestPrice":43.16,"committee":-0.016393,"eps":0,"divideRate":0.003299,"volume":289,"delay":0,"ttmEps":0,"open":43.16,"prevYearClose":36.3062,"prevWeekClose":40.9874,"prevMonthClose":41.805,"prevQuarterClose":39.9651,"fiveDayClose":41.0314,"twentyDayClose":42.8036,"sixtyDayClose":36.6303},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HELX\",params:#limit:5,,,undefined,":[{"date":"2025-12-30","symbol":"HELX","amount":0.14334,"announcedDate":"2025-12-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-30","defaultRemindTime":1767105000000,"name":"Franklin Genomic Advancements ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-08","payableDate":"2025-12-30","currency":"USD","dateTimestamp":1767070800000,"payDate":"2026-01-08"},{"market":"US","date":"2021-12-30","symbol":"HELX","amount":0.003935,"defaultRemindTime":1640874600000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2022-01-07","payableDate":"2021-12-31","currency":"USD","type":"dividend","dateTimestamp":1640840400000},{"market":"US","date":"2021-12-13","symbol":"HELX","amount":0.114148,"defaultRemindTime":1639405800000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2021-12-21","payableDate":"2021-12-14","currency":"USD","type":"dividend","dateTimestamp":1639371600000},{"market":"US","date":"2020-12-14","symbol":"HELX","amount":0.005005,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2020-12-23","payableDate":"2020-12-15","currency":"USD","type":"dividend","dateTimestamp":1607922000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HELX\",market:\"US\",,,undefined,":[{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-23","value":0.005005,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-21","value":0.114148,"currency":"USD"},{"executeDate":"2021-12-30","recordDate":"2021-12-31","paymentDate":"2022-01-07","value":0.003935,"currency":"USD"},{"executeDate":"2025-12-30","recordDate":"2025-12-30","paymentDate":"2026-01-08","value":0.14334,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HELX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HELX\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2655821999","title":"代謝紊亂生物技術公司Vogenx(VOGX.US)IPO定價11-13美元/股 擬募資7500萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2655821999","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655821999?lang=zh_tw&edition=fundamental","pubTime":"2026-07-30 16:15","pubTimestamp":1785399353,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，专注于开发内分泌和代谢紊乱疾病疗法、正处于2b期临床阶段的生物技术公司Vogenx于周三公布了其首次公开募股条款。这家总部位于北卡罗来纳州罗利市的公司计划通过以每股11至13美元的价格区间发行630万股股票，募集7500万美元资金。按拟议区间中点计算，Vogenx的完全稀释后市值将达到1.73亿美元。JonesTrading担任此次交易的唯一账簿管理人。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474046.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HELX","WDNA","IPOS","UUP","UDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655821967","title":"代謝紊亂生物技術公司Vogenx(VOGX.US)IPO定價11-13美元/股 擬募資7500萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2655821967","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655821967?lang=zh_tw&edition=fundamental","pubTime":"2026-07-30 16:15","pubTimestamp":1785399353,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HELX","UDN","IPOS","UUP","WDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654048086","title":"美國食品藥品監督管理局（FDA）批准了Freenome公司用於結直腸癌篩查的血液檢測","url":"https://stock-news.laohu8.com/highlight/detail?id=2654048086","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654048086?lang=zh_tw&edition=fundamental","pubTime":"2026-07-27 21:13","pubTimestamp":1785157998,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局批准了Freenome公司用于结直肠癌筛查的血液检测路透7月27日-两家公司周一表示，美国食品药品监督管理局已批准Freenome公司针对年龄较大的成年人的FRNM.O血液结直肠癌筛查检测，为合作伙伴雅培公司今秋在美国推出该产品铺平了道路。美国食品药品监督管理局批准该检测适用于45岁及以上中风险成年人，这使Freenome拥有了其首个商业化产品。根据2025年签署的商业化协议，Freenome将从雅培公司获得与此次批准相关的1亿美元里程碑付款。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nL4T43T12N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1721429741.USD","IHI","LU0058720904.USD","LU2237957902.USD","HELX","BK4568","IE00BJJMRZ35.SGD","LU1989763690.USD","SG9999004303.SGD","TMED","LU0170899867.USD","BK4082","BK4566","PJP","BK4551","LU2112291526.USD","LU0432979614.USD","LU0266013472.USD","LU2237957811.SGD","SGXZ23171101.USD","LU0868494617.USD","GNOM","BK4588","LFSC","LU0320765992.SGD","LU0234572021.USD","SG9999002224.SGD","GNMX","LU0882574055.USD","LU0122379950.USD","LU1989763427.SGD","LU2211815571.USD","LU1914381329.SGD","GDOC","LU0889565916.HKD","SG9999002232.USD","LU2133065610.SGD","BK4533","LU1061106388.HKD","PTH","GH","FRNM","IE00B2B36J28.USD","EKG","LU2468319806.SGD","IE0002141913.USD","ABT","BK4585","BK4535","FFOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654036699","title":"美股異動 | CRISPR基因編輯公司Scribe Therapeutics(SCTX.US)登陸美股市場 開盤後升逾59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654036699","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654036699?lang=zh_tw&edition=fundamental","pubTime":"2026-07-24 23:57","pubTimestamp":1784908651,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["GNOM","IDNA","KOMP","WDNA","BK4007","NBDS","LU1861558580.USD","BMED","BK4556","BK4539","LENZ","BK4611","SCTX","HELX","TARK","BK4588","LU1861559042.SGD","FWD","ARKG","XT","BK4585","DTEC","BK4139","SYNB","CRSP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154249418","title":"Krystal Biotech決定終止臨床研究，以推動KB801進入關鍵性試驗；SEC文件稱未觀察到安全性問題","url":"https://stock-news.laohu8.com/highlight/detail?id=1154249418","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154249418?lang=zh_tw&edition=fundamental","pubTime":"2026-07-22 05:27","pubTimestamp":1784669234,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会（SEC）的文件，Krystal Biotech Inc. 已决定终止一项临床研究，旨在将其候选药物KB801推进至关键性试验阶段。公司强调，此项决定并非基于任何安全性方面的考量，在研究中未观察到相关的安全性问题。\n该举措标志着公司对KB801开发策略的一次重要调整。通过提前终止当前研究，Krystal Biotech 计划更高效地集中资源，为后续更为关键的确证性试验阶段做准备。此举旨在加速该疗法的整体开发进程。\n公司表示，将继续对KB801项目保持专注，并致力于推进其临床开发计划。此次策略调整反映了公司在评估研发管线优先级和优化资源分配方面的持续努力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HELX","KRYS","BK4139","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169541881","title":"Krystal Biotech 披露：已終止研究無更多受試者數據更新，關鍵性試驗結果將適時公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1169541881","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169541881?lang=zh_tw&edition=fundamental","pubTime":"2026-07-22 05:27","pubTimestamp":1784669233,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会（SEC）的最新文件，Krystal Biotech Inc. 已明确表示，其一项已终止的研究将不再提供任何受试者层面的数据更新。公司同时指出，其关键性临床试验的最终结果将在适当的时候对外公布。\n这意味着，对于该特定研究项目，投资者及公众将无法期待获得更进一步的个体患者疗效或安全性细节。公司的研发重心与信息披露将集中于正在推进的关键性试验上，相关结果预计将按计划在未来适时发布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRYS","HELX","PSCH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653270150","title":"建築公司Tutor Perini入選標普小盤股股價大漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2653270150","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653270150?lang=zh_tw&edition=fundamental","pubTime":"2026-07-21 20:58","pubTimestamp":1784638720,"startTime":"0","endTime":"0","summary":"BUZZ-建筑公司Tutor Perini入选标普小盘股股价大涨7月21日-** 基础设施承包商Tutor PeriniTPC.N股价周二开盘前上涨6.7%，报85.93美元，因该公司即将被纳入标普小盘600指数.SPCY** 标普道琼斯指数公司周一晚间宣布，TPC将于7月24日（周五）起正式取代Krystal Biotech（KRYS.O）进入SPCY指数** KRYS将转入标普中盘400指数（","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nL4T43N14H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065169927.USD","KRYS","LU2065170008.USD","LU2065171402.SGD","PSCH","TMHC","BK4129","BK4139","HELX","BK4088","LU2065171311.SGD","TPC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653279706","title":"據彭博，總部位於美國的生物技術公司Axiom尋求在香港上市。","url":"https://stock-news.laohu8.com/highlight/detail?id=2653279706","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653279706?lang=zh_tw&edition=fundamental","pubTime":"2026-07-21 18:54","pubTimestamp":1784631279,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IPOS","HELX","WDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192230520","title":"標普道瓊斯指數宣佈：Krystal Biotech Inc.將取代Taylor Morrison Home Corporation進入標普400中型股指數","url":"https://stock-news.laohu8.com/highlight/detail?id=1192230520","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192230520?lang=zh_tw&edition=fundamental","pubTime":"2026-07-21 05:18","pubTimestamp":1784582294,"startTime":"0","endTime":"0","summary":"标普道琼斯指数公司宣布，将对标普400中型股指数（S&P MidCap 400）的成分股进行调整。根据公告，Krystal Biotech Inc. 将取代 Taylor Morrison Home Corporation 成为该指数的新成员。\n此次成分股变动是标普道琼斯指数公司定期评估与调整的一部分。指数成分股的调整通常基于市值、流动性以及行业代表性等多种因素。此番调整反映了市场结构的变化以及相关公司的发展状况。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRYS","HELX","PSCH","BK4139","BK4088","TMHC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651544879","title":"普洛藥業：擬1000萬元投資設立生物技術公司 構成關聯交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2651544879","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651544879?lang=zh_tw&edition=fundamental","pubTime":"2026-07-16 17:56","pubTimestamp":1784195802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HELX","WDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651160611","title":"億帆醫藥首個HMOs系列合成生物技術產品2'-FL取得食品生產許可證","url":"https://stock-news.laohu8.com/highlight/detail?id=2651160611","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651160611?lang=zh_tw&edition=fundamental","pubTime":"2026-07-13 11:39","pubTimestamp":1783913945,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["WDNA","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650168409","title":"特寶生物：生物技術創新融合及產業化基地項目主體結構封頂","url":"https://stock-news.laohu8.com/highlight/detail?id=2650168409","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650168409?lang=zh_tw&edition=fundamental","pubTime":"2026-07-12 17:34","pubTimestamp":1783848893,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HELX","WDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650344901","title":"港股異動丨生物技術板塊迎大反彈，銀諾醫藥隨行業暖風大升逾7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650344901","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650344901?lang=zh_tw&edition=fundamental","pubTime":"2026-07-10 12:17","pubTimestamp":1783657022,"startTime":"0","endTime":"0","summary":"在经历短暂调整后，港股市场生物技术股今日再度强势大涨。其中，银诺医药-B盘中拉升一度涨超7%，报8.56港元。　　银诺医药是一家专注于代谢性疾病领域创新药物研发及产业化的生物医药企业，拥有全自主研发管线，覆盖T1D、肥胖、MASH、AD 等适应症，具备全球知识产权及全球专利布局。　　消息面上，银诺医药7月9日针对近期沸沸扬扬的专利诉讼风波发表澄清声明。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202607/10/20260710866229.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202607/10/20260710866229.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260710/32303955.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["KCAI","VXUS","BK1161","HELX","02591","WDNA","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650978509","title":"Natera因癌症檢測獲得歐盟認證而股價上漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2650978509","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650978509?lang=zh_tw&edition=fundamental","pubTime":"2026-07-09 22:46","pubTimestamp":1783608388,"startTime":"0","endTime":"0","summary":"BUZZ-Natera因癌症检测获得欧盟认证而股价上涨7月9日-** 基因检测公司Natera（NTRA.O）股价上涨2.7%，至281.85美元** 该公司表示，其个性化癌症检测产品Signatera已获得欧盟诊断器械法规的认证** Signatera 用于检测治疗后可能残留的微量癌细胞，并监测癌症复发情况** 公司表示，Signatera是首款获得该欧盟认证的实体瘤个性化残留病灶检测产品** ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nL4T43B1B1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1988902786.USD","LU2065171311.SGD","LU2324357040.USD","LU0345770308.USD","LU0106261612.USD","GNOM","LU0963586101.USD","NTRA","LU2065171402.SGD","LU1064131342.USD","LU0053671581.USD","BK4139","LU2065170008.USD","LU0345770993.USD","LU0012050646.USD","LU2065169927.USD","LU2065731478.USD","HELX","LU2264538146.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649837966","title":"中國農科院生物所與華大智造共建「數字細胞時空組學實驗室」","url":"https://stock-news.laohu8.com/highlight/detail?id=2649837966","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649837966?lang=zh_tw&edition=fundamental","pubTime":"2026-07-08 15:42","pubTimestamp":1783496521,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HELX","WDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649197641","title":"生物技術公司Scribe Therapeutics(SCTX.US)申請美股IPO 擬籌資至多7500萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2649197641","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649197641?lang=zh_tw&edition=fundamental","pubTime":"2026-07-06 15:30","pubTimestamp":1783323045,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IPOS","HELX","LENZ","BK4007","BK4139","WDNA","KCE","FRHC","BK4539","BK4127"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":56,"code":"91000000","status":"200"}]}}